Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ICON Public Limited Company    ICLR   IE0005711209


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ICON Public : Wins Best CRO at the Vaccine Industry Excellence Awards

10/07/2020 | 05:01am EST

Award recognises ICON’s long-standing vaccine development expertise

ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced it has been awarded Best Clinical Research Organisation (CRO) at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place virtually last week.

The ViE awards were created to honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry. ICON was voted Best CRO by industry leaders asked to name their preferred CRO, and confirmed by a final judgement from a Scientific Advisory Board.

This marks the third time ICON has won the award. The company was awarded ViE Best CRO in 2017 and 2014, and has been named as a finalist every year since 2011, demonstrating a long history of excellence in vaccine research.

“We are extremely proud to be recognised as the world’s best CRO for vaccine development,” commented Dr Steve Cutler, ICON’s Chief Executive Officer. “The importance of vaccine research is more apparent now than ever before, with all eyes on the industry as the world waits in hope. This award is recognition of the continued hard work and dedication of the ICON vaccines team.”

Since February, ICON has mobilised its vaccine resources to address the COVID-19 global threat, including its ability to conduct home-based trials to minimise infection. The company is currently providing clinical monitoring and safety oversight on more than 100 COVID-19 trials for both the private and government sectors. These include a prophylactic vaccine study in healthy participants, and a study investigating antiviral treatment for patients with confirmed Coronavirus infection. ICON has conducted more than 246 vaccine studies globally, including over 40 studies in respiratory viruses, within the past five years alone.

ICON offers a fully integrated vaccine clinical development solution, from preclinical and laboratory services to comparative effectiveness using interventional, observational, and pragmatic methods. ICON’s services span the entire lifecycle of product development and can be adapted to suit small local trials or large global programmes. Prior to the COVID-19 pandemic, ICON’s vaccines team worked on trials involving the Ebola Virus, as well as earlier SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) outbreaks, on behalf of governments and NGOs, global biotech and pharmaceutical industry partners.

More information is available at www.iconplc.com/covid-19 and www.iconplc.com/vaccines.

A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 94 locations in 40 countries and has approximately 15,150 employees as of June 30, 2020.

Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.


© Business Wire 2020
01/12ICON PUBLIC : plc Presentation
01/07ICON PLC : to Present at the 39th Annual JP Morgan Healthcare Conference
01/04ICON PUBLIC : Supports Pfizer and BioNTech on the Investigational COVID-19 Vacci..
2020ICON PUBLIC : Releases First Environmental, Social and Governance Report
2020ICON PLC : to Present at the 29th Annual Credit Suisse Virtual Healthcare Confer..
2020ICON PUBLIC : plc Q3 2020 Presentation
2020ICON PUBLIC : Reports Third Quarter 2020 Results
2020ICON PUBLIC : BARDA reselects ICON as preferred partner to help strengthen US em..
2020ICON PUBLIC : Wins Best CRO at the Vaccine Industry Excellence Awards
2020ICON : Launches Accellacare a Global Clinical Research Network Focused on Increa..
More news
Financials (USD)
Sales 2020 2 789 M - -
Net income 2020 330 M - -
Net cash 2020 309 M - -
P/E ratio 2020 34,8x
Yield 2020 -
Capitalization 11 353 M 11 353 M -
EV / Sales 2020 3,96x
EV / Sales 2021 3,43x
Nbr of Employees 15 250
Free-Float 98,5%
Duration : Period :
ICON Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ICON PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 206,29 $
Last Close Price 215,12 $
Spread / Highest target 11,6%
Spread / Average Target -4,11%
Spread / Lowest Target -29,3%
EPS Revisions
Managers and Directors
Stephen A. Cutler Chief Executive Officer & Executive Director
Ciaran Murray Executive Chairman
Brendan Brennan Chief Financial Officer
Tom O'Leary Chief Information Officer
Anthony J. Japour Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.19.66%49 468
LONZA GROUP AG1.97%48 472
CELLTRION, INC.-12.95%38 667
SEAGEN INC.7.75%34 149